1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO 23: Concerns Despite Unprecedented Early-Stage Lung Cancer Win For Roche’s Alecensa

 
• By Kevin Grogan

The Swiss group's ALK inhibitor Alecensa improved disease-free survival by 76% in early-stage patients with the mutation, a first for the class, but an ESMO discussant raises questions about toxicity and treatment burden.

ESMO 2023 exterior
• Source: ESMO

Comfortably the market leader in treating advanced anaplastic lymphoma kinase (ALK)-positive lung cancer, the extent of the Phase III success of Roche Holding AG's Alecensa in tackling the early stage of the disease has caused a stir at the European Society for Medical Oncology congress in Madrid.

The Swiss major signalled in September that in the 257-patient Phase III ALINA study, Alecensa (alectinib) achieved an "unprecedented" improvement...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.